TOI Q4 2024 revenue up 16.9% to $100M; net loss narrows to $13.2M; 2025 guidance revenue $420-450M

Oncology Institute, Inc.

Revenue $100M (+16.9% YoY); net loss $13.2M vs $18.8M; EPS -$0.14 vs -$0.21.
Positive Q4 operating cash flow of $4.2M; SG&A down 12% YoY.
Added six new value-based contracts in H2 2024 covering over 250k lives; dispensary revenue at record.
2025 guidance: revenue $420-$450M, adjusted EBITDA loss $19-$24M, improved free cash flow.
New drug-supplier agreement expected to improve discounts and cost positioning.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.